Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer
Nona Biosciences and Atossa Therapeutics (Nasdaq: ATOS) have announced a research collaboration to develop next-generation therapeutic antibodies for breast cancer. The partnership will utilize Nona's proprietary H2L2 Harbour Mice® platform, which generates fully human monoclonal antibodies without requiring additional engineering or humanization.
The platform combines transgenic mice technology with single B cell cloning, offering an efficient approach to therapeutic antibody development. The Harbour Mice® platform has been implemented in over 250 drug discovery programs across multiple therapeutic areas and has gained widespread recognition from global partners.
Nona Biosciences e Atossa Therapeutics (Nasdaq: ATOS) hanno annunciato una collaborazione di ricerca per sviluppare anticorpi terapeutici di nuova generazione per il cancro al seno. La partnership utilizzerà la piattaforma proprietaria H2L2 Harbour Mice® di Nona, che genera anticorpi monoclonali completamente umani senza richiedere ingegnerizzazione o umanizzazione aggiuntive.
La piattaforma combina tecnologia dei topi transgenici con clonazione di singole cellule B, offrendo un approccio efficiente allo sviluppo di anticorpi terapeutici. La piattaforma Harbour Mice® è stata implementata in oltre 250 programmi di scoperta di farmaci in diverse aree terapeutiche e ha guadagnato un ampio riconoscimento da parte di partner globali.
Nona Biosciences y Atossa Therapeutics (Nasdaq: ATOS) han anunciado una colaboración de investigación para desarrollar anticuerpos terapéuticos de nueva generación para el cáncer de mama. La asociación utilizará la plataforma H2L2 Harbour Mice® de Nona, que genera anticuerpos monoclonales completamente humanos sin requerir ingeniería o humanización adicional.
La plataforma combina tecnología de ratones transgénicos con clonación de células B individuales, ofreciendo un enfoque eficiente para el desarrollo de anticuerpos terapéuticos. La plataforma Harbour Mice® se ha implementado en más de 250 programas de descubrimiento de fármacos en múltiples áreas terapéuticas y ha ganado un amplio reconocimiento por parte de socios globales.
노나 바이오사이언스와 아토사 제약 (나스닥: ATOS)가 유방암을 위한 차세대 치료 항체 개발을 위한 연구 협력을 발표했습니다. 이 파트너십은 추가적인 공학이나 인간화 없이 완전 인간 단클론 항체를 생성하는 노나의 독점 H2L2 하버 마우스® 플랫폼을 활용합니다.
이 플랫폼은 트랜스제닉 쥐 기술과 단일 B 세포 클로닝을 결합하여 치료 항체 개발에 효율적인 접근 방식을 제공합니다. 하버 마우스® 플랫폼은 여러 치료 분야에서 250개 이상의 약물 발견 프로그램에 구현되었으며, 글로벌 파트너들로부터 광범위한 인정을 받았습니다.
Nona Biosciences et Atossa Therapeutics (Nasdaq: ATOS) ont annoncé une collaboration de recherche pour développer des anticorps thérapeutiques de nouvelle génération pour le cancer du sein. Ce partenariat utilisera la plateforme H2L2 Harbour Mice® de Nona, qui génère des anticorps monoclonaux entièrement humains sans nécessiter d'ingénierie ou d'humanisation supplémentaires.
La plateforme combine la technologie des souris transgéniques avec le clonage de cellules B uniques, offrant une approche efficace pour le développement d'anticorps thérapeutiques. La plateforme Harbour Mice® a été mise en œuvre dans plus de 250 programmes de découverte de médicaments dans plusieurs domaines thérapeutiques et a reçu une large reconnaissance de la part de partenaires mondiaux.
Nona Biosciences und Atossa Therapeutics (Nasdaq: ATOS) haben eine Forschungskooperation angekündigt, um Therapeutika der nächsten Generation für Brustkrebs zu entwickeln. Die Partnerschaft wird Nona's proprietäre H2L2 Harbour Mice®-Plattform nutzen, die vollständig humane monoklonale Antikörper ohne zusätzliche Ingenieur- oder Humanisierungsmaßnahmen erzeugt.
Die Plattform kombiniert transgene Mäuse-Technologie mit der Klonierung einzelner B-Zellen und bietet einen effizienten Ansatz zur Entwicklung therapeutischer Antikörper. Die Harbour Mice®-Plattform wurde in über 250 Arzneimittelentdeckungsprogrammen in verschiedenen therapeutischen Bereichen eingesetzt und hat weltweit Anerkennung von globalen Partnern erhalten.
- Strategic partnership to develop novel breast cancer therapies
- Access to proven Harbour Mice® platform with track record of 250+ drug discovery programs
- Technology eliminates need for additional antibody engineering, potentially accelerating development timeline
- Early-stage research collaboration with no guaranteed success
- No specific timeline or financial terms disclosed
Nona Biosciences' proprietary Harbour Mice® platform employs transgenic mice to generate fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format, eliminating the need for additional engineering or humanization. Combined with the single B cell cloning technology, this platform offers a powerful approach to developing therapeutic antibodies and accelerating drug discovery and development. To date, Harbour Mice® platform has been applied in more than 250 drug discovery programs across multiple therapeutic areas and has been widely recognized by global partners.
"We are pleased to collaborate with Atossa Therapeutics to discover next-generation antibody therapies for breast cancer," said Jingsong Wang, M.D., Ph.D., Chairman of Nona Biosciences. "This partnership highlights the value of our proprietary Harbour Mice® platform and reflects the industry's growing demand for innovative antibody discovery solutions. With Nona's industry-leading technology and expertise, we look forward to supporting Atossa's exploration of antibody-based approaches within their oncology pipeline."
About Nona Biosciences
Nona Biosciences is a global biotechnology company committed to cutting-edge technology innovations and providing a total solution from "Idea to IND" ("I to ITM"), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team.
Harbour Mice® generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain-only (HCAb) format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit: www.nonabio.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nona-biosciences-and-atossa-therapeutics-partner-to-discover-next-generation-antibody-therapies-for-breast-cancer-302425464.html
SOURCE Nona Biosciences
FAQ
What is the purpose of the collaboration between Nona Biosciences and Atossa Therapeutics (ATOS)?
How does the Harbour Mice® platform used in ATOS collaboration work?
How many drug discovery programs has the Harbour Mice® platform been used in?
What specific technology will ATOS use in this breast cancer research collaboration?
